TRAF3 as a potential diagnostic biomarker for recurrent pregnancy loss: insights from single-cell transcriptomics and machine learning
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: Discovery uses single-cell data and follow-up expression/clinical validation; molecular docking is exploratory.
Technology: Single-cell transcriptomics and machine-learning feature selection identify TRAF3 as a candidate recurrent-pregnancy-loss marker; RT-PCR and immunohistochemistry provide clinical-sample validation.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Single-cell transcriptomics and machine-learning feature selection identify TRAF3 as a candidate recurrent-pregnancy-loss marker; RT-PCR and immunohistochemistry provide clinical-sample validation.
- Limitation / still unknown
- The result is limited to the reported dataset, experimental setting and validation in this study; broader generalization and real-world benefit are not established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://europepmc.org/article/MED/40450232 · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC12125721/unicode · https://pubmed.ncbi.nlm.nih.gov/40450232/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.